Skip to Content

Funding Opportunities

Current Funding Opportunities RSS

  • Centers of Excellence for Big Data Computing in the Biomedical Sciences (U54)

    Source: RFA-HG-13-009

    • Release Date: July 30, 2013
    • Application Receipt Date: November 20, 2013
    • Expiration Date: November 21, 2013
    • Contacts:

      Peter Lyster, Ph.D.
      Division of Biomedical Technology, Bioinformatics, and Computational Biology
      National Institute of General Medical Sciences (NIGMS)
      Telephone: 301-594-3928
      Email:  BD2KCenterRFA@mail.nih.gov

      Lisa Brooks, Ph.D.
      Division of Genome Sciences
      National Human Genome Research Institute (NHGRI)
      Telephone: 301-435-5544
      Email: BD2KCenterRFA@mail.nih.gov 

    This FOA solicits applications for Centers of Excellence for Big Data Computing in the Biomedical Sciences (U54).  Each BD2K Center award will support a multi-investigator, interdisciplinary team working collaboratively to develop innovative approaches to address a major challenge to the effective use of Big Data for a broad and important biomedical research problem(s).  (As noted, the term “biomedical” is being used here in the broadest sense to include biological, biomedical, behavioral, social, environmental, and clinical studies that relate to understanding health and disease.)  The center grant activity code is being used for this FOA to solicit research projects that could not be achieved by smaller and more limited activity codes (other BD2K FOAs will be issued to solicit single investigator-initiated projects).  A BD2K Center application is expected to propose the development of specific and substantive “products” -- e.g., approaches, methods, software, tools, and other resources to analyze data -- and then distribute the products to the user community to dramatically enhance the research community's capabilities for using Big Data in biomedical research.  In addition, by training young and established investigators, the BD2K Centers will contribute, along with other BD2K programs, to the expansion of the pool of researchers who are able to use and develop methods to work with Big Data in biomedical research.

    The range of opportunities that is opened up by the growing capabilities for generating Big Data spans the gamut of biomedical sciences, and the challenges to making the benefits of Big Data available to all investigators are significant.  However, NIH is not expecting a single BD2K Center to address all areas and all needs of Big Data challenges. As noted by the Data and Informatics Working Group of the Advisory Committee to the NIH Director, there will be significant benefits from interactions among the BD2K Centers, since synergistic interactions among the Centers and between the Centers and the larger research community can result in an impact of the BD2K Center Program that is much broader than the sum of the individual Centers’ activities.  Therefore, BD2K Centers, once funded, will be expected to form a BD2K Center Consortium, within which each center is expected to interact and collaborate with other Centers in the consortium.  They are also encouraged to interact and collaborate with other domestic or international efforts in the science of Big Data outside the consortium.

    The primary research focus of a BD2K Center will be research and development in one or more areas that may include approaches, methods, software, tools, and other resources that enable data release, acquisition, storage, distribution, management (e.g., approaches for developing databases, data and metadata formats and standards, ontologies, and interoperability, etc.), processing, annotation, visualization, statistical and computational analysis, integration, simulation, and modeling.  The BD2K Centers should include diverse expertise and could involve investigators not only from the biomedical sciences, but also from the physical, quantitative, and related science disciplines that have developed cutting-edge approaches to address Big Data challenges.

    The methods and scientific results should be published, and the software, tools, and resources should be made available to the community.  Since the BD2K Centers will be NIH-funded through the current mechanism for a finite duration, the Centers should propose plans to ensure the continued distribution of the methods and software after the end of the NIH funding period.

  • CPTAC Program Phase II Biospecimen Collection

    Source: Fort Detrick Business Development Office

    • Release Date: June 13, 2013

    A funding opportunity in support of the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) seeks to prospectively procure tumor samples, collected for proteomics investigation. The scope of work under this Statement of Work encompasses the activities needed to prospectively procure high quality, clinically annotated human tumor samples, blood and serum, and when feasible normal tissue from volunteer patients suffering from colon, ovarian, and breast cancer. The tissue will be utilized for CPTAC Program with the samples obtained under conditions optimized for proteomic analysis.

    For more information about this solicitation and updates visit the Fort Detrick Business Development Office site at http://www.fdbdo.com/s13-088.
    NAICS Code(s): 5417

    Primary Contact: shaneeka.owens-bearden@nih.gov

    Fax: 301-228-4037

View All »

Launch Antibody Portal »

The Antibody Portal serves as a public resource of well-characterized monoclonal antibodies made available by the NCI for the scientific community.

Launch Data Portal »

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) Data Portal provides a platform for researchers to search, download, and analyze data sets generated by CPTAC.